HEALTH● LOWJul 22 · Jul 22, 2026, 9:27 PM
Pfizer gains priority review for Talzenna/Xtandi combo in prostate cancer
Seeking Alpha Tech
Pfizer has received priority review for its combination drug, Talzenna/Xtandi, for treating prostate cancer. This development could accelerate the availability of a new therapeutic option for patients.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH37m ago UNBREAKABLE on BrightU : Inside the psychology of becoming UNBREAKABLE – NaturalNews . comnaturalnews.com · United StatesHEALTH37m agoEsther Rantzen daughter heartbreaking six words as she tells mum assisted dying resultaol.co.uk · United KingdomHEALTH1h agoCleaner cooking stoves offer hope for 1 billion Africans using wood, charcoalAfricanews [en]HEALTH1h agoDiphtheria Outbreak: ActionAid expresses concern over death of 2 children in FCTVanguard Nigeria